Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses

Virology

Volumn 476, Issue , 2015, Pages 85-91

  Albariño, César G ^a   Wiggleton Guerrero, Lisa ^a   Spengler, Jessica R ^a   Uebelhoer, Luke S ^a   Chakrabarti, Ayan K ^a   Nichol, Stuart T ^a   Towner, Jonathan S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Bat virus; Central basic; Ebola virus; Filovirus; IFN antagonism; Immune modulatory; Marburg virus; Patch; VP35

Indexed keywords

INTERFERON INHIBITORY DOMAIN PROTEIN; PROTEIN VP35; UNCLASSIFIED DRUG; VIRUS PROTEIN; BETA INTERFERON; CORE PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MARBURG VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVERSE GENETICS; SPECIES COMPARISON; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; CELL LINE; CHEMISTRY; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MARBURG HEMORRHAGIC FEVER; MUTATION; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MARBURGVIRUS;

ANIMALS; CELL LINE; HOST-PATHOGEN INTERACTIONS; INTERFERON-BETA; MARBURG VIRUS DISEASE; MARBURGVIRUS; MUTATION; PROTEIN STRUCTURE, TERTIARY; VIRAL CORE PROTEINS;

EID: 84919360204     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.12.002     Document Type: Article

References (39)

1. Albarino C.G., Shoemaker T., Khristova M.L., Wamala J.F., Muyembe J.J., Balinandi S., Tumusiime A., Campbell S., Cannon D., Gibbons A., Bergeron E., Bird B., Dodd K., Spiropoulou C., Erickson B.R., Guerrero L., Knust B., Nichol S.T., Rollin P.E., Stroher U. Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. Virology 2013, 442:97-100.
2. Albarino C.G., Uebelhoer L.S., Vincent J.P., Khristova M.L., Chakrabarti A.K., McElroy A., Nichol S.T., Towner J.S. Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. Virology 2013, 446:230-237.
3. Bale S., Julien J.P., Bornholdt Z.A., Kimberlin C.R., Halfmann P., Zandonatti M.A., Kunert J., Kroon G.J., Kawaoka Y., MacRae I.J., Wilson I.A., Saphire E.O. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog. 2012, 8:e1002916.
4. Bale S., Julien J.P., Bornholdt Z.A., Krois A.S., Wilson I.A., Saphire E.O. Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism. J. Virol. 2013, 87:10385-10388.
5. Basler M., Youhnovski N., Van Den Broek M., Przybylski M., Groettrup M. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 2004, 173:3925-3934.
6. Baum A., Garcia-Sastre A. Differential recognition of viral RNA by RIG-I. Virulence 2011, 2:166-169.
7. Buchholz U.J., Finke S., Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 1999, 73:251-259.
8. Cardenas W.B., Loo Y.M., Gale M., Hartman A.L., Kimberlin C.R., Martinez-Sobrido L., Saphire E.O., Basler C.F. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80:5168-5178.
9. Edwards M.R., Johnson B., Mire C.E., Xu W., Shabman R.S., Speller L.N., Leung D.W., Geisbert T.W., Amarasinghe G.K., Basler C.F. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep. 2014, 6:1017-1025.
10. Fabozzi G., Nabel C.S., Dolan M.A., Sullivan N.J. Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 2011, 85:2512-2523.
11. Feldmann H., Sanchez A., Geisbert T.W. Filoviridae: Marburg and Ebola viruses. Fields Virology 2013, 923-956. Lippincott, Williams and Wilkins, Philadelphia. Sixth ed. D. Knipe, H. P.M (Eds.).
12. Hartman A.L., Bird B.H., Towner J.S., Antoniadou Z.A., Zaki S.R., Nichol S.T. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 2008, 82:2699-2704.
13. Hartman A.L., Dover J.E., Towner J.S., Nichol S.T. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 2006, 80:6430-6440.
14. Hartman A.L., Towner J.S., Nichol S.T. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004, 328:177-184.
15. Hartman A.L., Towner J.S., Nichol S.T. Ebola and marburg hemorrhagic fever. Clin. Lab. Med. 2010, 30:161-177.
16. Leroy E.M., Gonzalez J.P., Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin. Microbiol. Infec.: Off. Publ. Eur. Soc. Clin. Microbiol. Infec. Dis. 2011, 17:964-976.
17. Leung D.W., Ginder N.D., Fulton D.B., Nix J., Basler C.F., Honzatko R.B., Amarasinghe G.K. Structure of the Ebola VP35 interferon inhibitory domain. P. Natl. Acad. Sci. USA. 2009, 106:411-416.
18. Leung D.W., Prins K.C., Borek D.M., Farahbakhsh M., Tufariello J.M., Ramanan P., Nix J.C., Helgeson L.A., Otwinowski Z., Honzatko R.B., Basler C.F., Amarasinghe G.K. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 2010, 17:165-172.
19. Luthra P., Ramanan P., Mire C.E., Weisend C., Tsuda Y., Yen B., Liu G., Leung D.W., Geisbert T.W., Ebihara H., Amarasinghe G.K., Basler C.F. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe 14 2013, 74-84.
20. Mateo M., Carbonnelle C., Reynard O., Kolesnikova L., Nemirov K., Page A., Volchkova V.A., Volchkov V.E. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J. Infect. Dis. 2011, 204(Suppl 3)):S1011-S1020.
21. Mateo M., Reid S.P., Leung L.W., Basler C.F., Volchkov V.E. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 2010, 84:1169-1175.
22. McElroy A.K., Nichol S.T. Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 2012, 422:6-12.
23. McMullan L.K., Frace M., Sammons S.A., Shoemaker T., Balinandi S., Wamala J.F., Lutwama J.J., Downing R.G., Stroeher U., MacNeil A., Nichol S.T. Using next generation sequencing to identify yellow fever virus in Uganda. Virology 2012, 422:1-5.
24. Mohan G.S., Li W., Ye L., Compans R.W., Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 2012, 8:e1003065.
25. Negredo A., Palacios G., Vazquez-Moron S., Gonzalez F., Dopazo H., Molero F., Juste J., Quetglas J., Savji N., de la Cruz Martinez M., Herrera J.E., Pizarro M., Hutchison S.K., Echevarria J.E., Lipkin W.I., Tenorio A. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog. 2011, 7:e1002304.
26. Page A., Volchkova V.A., Reid S.P., Mateo M., Bagnaud-Baule A., Nemirov K., Shurtleff A.C., Lawrence P., Reynard O., Ottmann M., Lotteau V., Biswal S.S., Thimmulappa R.K., Bavari S., Volchkov V.E. Marburgvirus hijacks nrf2-dependent pathway by targeting nrf2-negative regulator keap1. Cell Rep. 2014, 6:1026-1036.
27. Prins K.C., Binning J.M., Shabman R.S., Leung D.W., Amarasinghe G.K., Basler C.F. Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J. Virol. 2010, 84:10581-10591.
28. Prins K.C., Cardenas W.B., Basler C.F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 2009, 83:3069-3077.
29. Prins K.C., Delpeut S., Leung D.W., Reynard O., Volchkova V.A., Reid S.P., Ramanan P., Cardenas W.B., Amarasinghe G.K., Volchkov V.E., Basler C.F. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 2010, 84:3004-3015.
30. Ramanan P., Edwards M.R., Shabman R.S., Leung D.W., Endlich-Frazier A.C., Borek D.M., Otwinowski Z., Liu G., Huh J., Basler C.F., Amarasinghe G.K. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. P. Natl. Acad. Sci. USA. 2012, 109:20661-20666.
31. Ramanan P., Shabman R.S., Brown C.S., Amarasinghe G.K., Basler C.F., Leung D.W. Filoviral immune evasion mechanisms. Viruses 2011, 3:1634-1649.
32. Reid S.P., Leung L.W., Hartman A.L., Martinez O., Shaw M.L., Carbonnelle C., Volchkov V.E., Nichol S.T., Basler C.F. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 2006, 80:5156-5167.
33. Reid S.P., Valmas C., Martinez O., Sanchez F.M., Basler C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2007, 81:13469-13477.
34. Uebelhoer L.S., Albarino C.G., McMullan L.K., Chakrabarti A.K., Vincent J.P., Nichol S.T., Towner J.S. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antivir. Res. 2014, 106:86-94.
35. Valmas C., Basler C.F. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 2011, 85:4309-4317.
36. Valmas C., Grosch M.N., Schumann M., Olejnik J., Martinez O., Best S.M., Krahling V., Basler C.F., Muhlberger E. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 2010, 6:e1000721.
37. Yoneyama M., Suhara W., Fukuhara Y., Sato M., Ozato K., Fujita T. Autocrine amplification of type I interferon gene expression mediated by interferon stimulated gene factor 3 (ISGF3). J. Biochem. 1996, 120:160-169.
38. Zhu Y., Cherukuri N.C., Jackel J.N., Wu Z., Crary M., Buckley K.J., Bisaro D.M., Parris D.S. Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells. J. Virol. 2012, 86:3038-3049.
39. Zinzula L., Esposito F., Pala D., Tramontano E. dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35. Antivir. Res. 2012, 93:354-363.